[Biological myolysis during combined fenofibrate-pravastatin therapy].
The authors report a case of biological myolysis related to combined fenofibrate-pravastatin therapy in the course of a change in treatment. This case suggests that the risk of myolysis is not specific to the association of some compounds of the two classes but is inherent in possible combinations of drugs from these two families. One must therefore abstain from prescribing these two classes of drugs, since there is no evidence that the combination is preferable to the HMG CoA inhibitor administered alone and the risk of iatrogenic complications is increased. Finally, during the passage from fibrate to HMG CoA reductase a treatment-free interval of about one week should be mandatory.
Raimondeau
J
J
Clinique cardiologique et des Maladies vasculaires, Hôpital Laennec, CHRU, Nantes.
Le Marec
H
H
Chevallier
J C
JC
Bouhour
J B
JB
D000787:Angina Pectoris / Q000188:drug therapy*; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D011345:Fenofibrate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects* / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000097:blood / Q000139:chemically induced*
D003402:Creatine Kinase; D017035:Pravastatin; D011345:Fenofibrate
Myolyse biologique survenue à l'occasion d'un relais thérapeutique fénofibrate-pravastatine.